Ramírez-Vidal Lizbeth, Becerril-Rico Jared, Monroy-Mora Alberto, Tinajero-Rodríguez Jose Manuel, Centeno-Cruz Federico, Oñate-Ocaña Luis F, Ortiz-Sánchez Elizabeth
Posgrado de Ciencias Biomédicas, Facultad de Medicina, Universidad Nacional Autónoma de México, Circuito Exterior s/n Ciudad Universitaria, Coyoacán, Mexico City 04510, Mexico.
Programa de Maestría en Ciencias Biológicas, Universidad Nacional Autónoma de México, Circuito Exterior s/n Ciudad Universitaria, Coyoacán, Mexico City 04510, Mexico.
Diagnostics (Basel). 2024 Jul 26;14(15):1614. doi: 10.3390/diagnostics14151614.
Gastric cancer (GC) is a leading cause of death, and this pathology often receives a diagnosis in an advanced stage. The development of a less invasive and cost-effective test for detection is essential for decreasing the mortality rate and increasing the life expectancy of GC patients. We evaluated the potential targeting of CD54/ICAM1, a marker of gastric cancer stem cells, with miRNAs to detect GC in blood samples. The analyses included 79 blood samples, 38 from GC patients and 41 from healthy donors, who attended INCan, México City. The total RNA was obtained from the blood plasma, and RT-PCR and qPCR were performed to obtain the relative expression of each miRNA. Hsa-miR-335-5p was detected in the plasma of GC patients and healthy donors at the same levels. The ROC curve analyses indicated that this miRNA was not a candidate for the molecular diagnosis of GC. We did not observe a correlation between the expression of hsa-miR-335-5p and clinical variables; however, the Kaplan-Meier analyses indicated that, in patients who survived more than 12 months, a lower expression of hsa-miR-335-5p was correlated with a better prognosis. It would be convenient to evaluate a larger panel of miRNAs, including miRNAs expressed in a limited number of cell types or with a low number targets, to obtain more specific candidates for developing a robust test for the diagnosis/prognosis of GC.
胃癌（GC）是主要的死亡原因之一，这种病理状况通常在晚期才被诊断出来。开发一种侵入性较小且成本效益高的检测方法对于降低胃癌患者的死亡率和提高其预期寿命至关重要。我们评估了利用微小RNA（miRNA）靶向胃癌干细胞标志物CD54/ICAM1以检测血样中胃癌的可能性。分析纳入了79份血样，其中38份来自胃癌患者，41份来自墨西哥城国家癌症研究所（INCan）的健康献血者。从血浆中提取总RNA，并进行逆转录聚合酶链反应（RT-PCR）和定量聚合酶链反应（qPCR）以获得每种miRNA的相对表达量。在胃癌患者和健康献血者的血浆中检测到的人源miR-335-5p水平相同。ROC曲线分析表明，这种miRNA不是胃癌分子诊断的候选标志物。我们未观察到hsa-miR-335-5p的表达与临床变量之间存在相关性；然而，Kaplan-Meier分析表明，在存活超过12个月的患者中，hsa-miR-335-5p的低表达与较好的预后相关。评估更多的miRNA组合会很方便，包括在有限数量细胞类型中表达或靶标数量较少的miRNA，以获得更具特异性的候选标志物，从而开发出一种强大的胃癌诊断/预后检测方法。
